J. Andrew Pospisilik
Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany


PhD in Physiology at UBC demonstrating therapeutic potential of DPIV-inhibition, work that would help launch development and clinical use of DPIV inhibitors. Postdoctoral work at IMBA using mouse genetics to disproved the link between mitochondrial dysfunction and peripheral insulin resistance, showing that mitochondrial inefficiency actually can prevent type-2 diabetes and obesity. His later work moved into functional systems epigenomics and included screening the world’s first transgenic-RNAi fly for obesity regulators, efforts that led to the discovery of Hedgehog as one of the first known controllers of good (brown) versus bad (white) fat. In addition to developing these ideas further, Andrew's most recent and future goals have been to chart the non-genetic origins of phenotypic variation and how such mechanisms steer evolution, adaptation and disease. Andrew is indebted and honored at past and ongoing support from the EU, ERC, DFG, WWTF, BMBF, NIH and Max Planck Society, and at awards such as the EASD Rising Star Award, GSK Award for Basic Medical Research, and the Helmholtz Young Investigator in Diabetes award.